Inhibrx 2022 Investor Presentation - Clinical Pipeline Update

Inhibrx, Inc. is a clinical-stage biopharmaceutical company developing novel oncology and rare disease therapeutics, including tetravalent and hexavalent agonists and an AAT-Fc fusion protein. The presentation outlines the company's pipeline progress with multiple programs in clinical trials, including INBRX-109, INBRX-106, INBRX-105, and AAT-Fc candidates for cancer, AATD, and GvHD indications, with potential peak sales projections exceeding $3 billion.